Atrium Therapeutics Inc (RNA) 재무 분석
*모든 숫자는 백만 단위입니다.
| 기간 종료일 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|---|
| 기간 | 3개월 | 3개월 | 3개월 | 3개월 | 3개월 |
| Revenues | 410.02%15.32 | 3.00 | 19.64 | 0.86 | 12.48 |
14.33%21.95 | 25.62 | 36.92 | 255.34 | 201.28 | |
| Research and Development | 10.08%13.80 | 15.34 | 16.66 | 166.60 | 154.95 |
| Operating Income/Loss | 70.69%-6.63 | -22.62 | -17.28 | -254.48 | -188.81 |
| Nonoperating Income/Loss | 2.84%2.36 | 2.43 | 0.65 | 17.38 | 14.36 |
| Income/Loss From Continuing Operations Before Tax | -4.27 | - | - | -237.10 | 12.48 |
| Income Tax Expense/Benefit | - | - | - | - | - |
78.87%-4.27 | -20.19 | -16.63 | -237.10 | -174.44 | |
| Attributable To Parent | 78.87%-4.27 | -20.19 | -16.63 | -237.10 | -174.44 |
| Basic Average Shares | 0.40%17.04 | 17.11 | 17.11 | 5.43 | 137.90 |
| Diluted Average Shares | 0.40%17.04 | 17.11 | 17.11 | 5.43 | 137.90 |
| Basic Earnings Per Share | 78.81%-0.25 | -1.18 | -0.97 | -1.59 | -1.27 |
| Diluted Earnings Per Share | 78.81%-0.25 | -1.18 | -0.97 | -1.59 | -1.27 |